Theory Paper IDrNB Cardiology – Theory Notes

EISENMENGER SYNDROME: PATHOPHYSIOLOGY AND MANAGEMENT

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION AND CORE PATHOPHYSIOLOGY

  • The Definition: Eisenmenger Syndrome (ES) is the end-stage clinical phenotype of an untreated, large systemic-to-pulmonary cardiovascular communication—including pre-tricuspid shunts (Atrial Septal Defect [ASD]) and post-tricuspid shunts (Ventricular Septal Defect [VSD], Patent Ductus Arteriosus [PDA], Aortopulmonary Window, or Atrioventricular Septal Defect [AVSD]).
  • The Vascular Transition: Chronic exposure of the pulmonary vascular bed to augmented pulmonary blood flow (shear stress) and systemic arterial pressure triggers endothelial dysfunction (imbalance of increased Endothelin-1 and Thromboxane A2 with reduced Nitric Oxide and Prostacyclin), smooth muscle hypertrophy, intimal fibrosis, plexiform lesions, and necrotizing arteritis—culminating in irreversible Pulmonary Vascular Obstructive Disease (PVOD) (Heath-Edwards Grades IV to VI).
  • The Hemodynamic Result: Once Pulmonary Vascular Resistance (PVR) approaches or exceeds Systemic Vascular Resistance (SVR), the original left-to-right shunt becomes bidirectional or reverses to right-to-left (R-to-L), producing chronic central or differential cyanosis.

IICLINICAL PRESENTATION AND MULTI-ORGAN INVOLVEMENT

  • Central vs. Differential Cyanosis and Clubbing: Generalized central cyanosis and digital clubbing occur in intracardiac shunts (VSD, ASD), whereas differential cyanosis and clubbing (pink fingers with cyanotic, clubbed toes) is pathognomonic of an Eisenmenger PDA, as deoxygenated right ventricular blood shunts into the descending aorta distal to the left subclavian artery.
  • Secondary Erythrocytosis and Hyperviscosity: Chronic tissue hypoxia upregulates renal Erythropoietin (EPO) production, increasing red blood cell mass and hematocrit (often exceeding 60 to 65 percent). Decompensated hyperviscosity manifests as headache, dizziness, tinnitus, visual disturbances, lethargy, and paresthesias.
  • Paradoxical Hemostatic Abnormalities (Bleeding and Thrombosis):
    • Bleeding Diathesis: Driven by thrombocytopenia, abnormal platelet function, depletion of high-molecular-weight von Willebrand factor multimers from high vascular shear stress, and impaired hepatic synthesis of vitamin K-dependent clotting factors. Manifests as epistaxis, gingival bleeding, menorrhagia, and life-threatening hemoptysis (from rupture of fragile bronchial/aortopulmonary collaterals or pulmonary infarction).
    • Thrombotic Diathesis: Driven by sluggish dilated pulmonary arteries, endothelial injury, secondary erythrocytosis, and iron-deficient microcytosis. Up to 20 to 30 percent develop proximal pulmonary artery in-situ thrombosis, alongside high risk of paradoxical cerebral embolism (stroke) and brain abscess (due to right-to-left shunting bypassing the pulmonary capillary phagocytic filter).
    • Arrhythmias and Sudden Cardiac Death: Chronic right atrial and right ventricular stretch/fibrosis predispose to Atrial Flutter, Atrial Fibrillation, intra-atrial reentrant tachycardia, and malignant ventricular arrhythmias.
    • Renal, Hepatobiliary, and Skeletal Complications: Hyperuricemia and clinical gout result from increased erythroid nucleoprotein turnover combined with reduced renal urate fractional excretion. Chronic glomerular hyperfiltration and hypoxia cause cyanotic nephropathy (glomerulomegaly, focal segmental glomerulosclerosis, and proteinuria), while chronic heme breakdown causes calcium bilirubinate (pigment) gallstones and periosteal reaction causes hypertrophic osteoarthropathy.

IIIDIAGNOSTIC WORKUP AND HEMODYNAMIC CRITERIA (ESC 2020 / ESC-ERS 2022)

  • Transthoracic and Transesophageal Echocardiography: Demonstrates the underlying defect with low-velocity bidirectional or right-to-left shunting (note: the high-velocity murmur of a VSD or the continuous machinery murmur of a PDA disappears once Eisenmenger physiology develops, replaced by a loud palpable P2, pulmonary ejection click, and high-pitched Graham Steell murmur of pulmonary regurgitation), marked RV hypertrophy, and flattened interventricular septum.
  • Right Heart Catheterization (RHC): Confirms pre-capillary pulmonary hypertension (mPAP greater than 20 mmHg, PAWP 15 mmHg or less, PVR greater than 2 Wood Units) with systemic or suprasystemic pulmonary pressures and net right-to-left or bidirectional shunting (Qp:Qs less than 1.0 to 1.5).
  • Operability vs. Inoperability Criteria (2020 ESC ACHD Guidelines):
    • Operable (Class I): PVR less than 3 Wood Units (WU) with Qp:Qs 1.5 or greater.
    • Borderline (Class IIa / IIb): PVR 3 to less than 5 WU with Qp:Qs greater than 1.5 (Class IIa for ASD/VSD/PDA).
    • Inoperable / Eisenmenger (Class III — Harm): Persistent PVR of 5 WU or greater (or indexed PVR greater than 8 WU·m2) despite targeted PAH therapy, or Qp:Qs less than 1.5, or resting/exercise arterial desaturation. (Note: Per ESC 2020 guidelines, acute vasodilator testing during RHC is not recommended to decide defect closure in adults with PAH-CHD.)

IVEVIDENCE-BASED MANAGEMENT (ESC 2020 ACHD / ESC-ERS 2022 PH GUIDELINES)

ATargeted PAH Pharmacotherapy

  • Endothelin Receptor Antagonists (ERAs — First-Line):
    • Bosentan (Class I, Level B): The landmark double-blind randomized BREATHE-5 Trial (Circulation 2006) proved that Bosentan (62.5 mg BD for 4 weeks, then 125 mg BD) significantly reduced PVR index and improved 6-Minute Walk Distance (by +53.1 meters) in WHO Functional Class III Eisenmenger patients without worsening systemic arterial oxygen saturation (SpO2). Requires monthly hepatic transaminase monitoring.
    • Macitentan (MAESTRO Trial): Although the Phase III MAESTRO Trial (2019) missed its primary 6MWD endpoint in the overall heterogeneous Eisenmenger cohort (which included Down syndrome), it significantly reduced NT-proBNP and lowered PVR in the hemodynamic substudy, and is widely used due to absence of hepatotoxicity.
    • Phosphodiesterase-5 (PDE-5) Inhibitors and sGC Stimulators (Class IIa): Sildenafil (20 mg TID) and Tadalafil (20 to 40 mg OD) improve exercise capacity, functional class, and survival in observational registries, and are routinely used in upfront or sequential combination therapy with an ERA.
    • Prostanoids / Prostacyclin Receptor Agonists (Class IIa): Inhaled Iloprost, Subcutaneous Treprostinil, or oral Selexipag are preferred for patients remaining in WHO Functional Class III/IV despite oral combination therapy; continuous intravenous Epoprostenol is generally avoided unless strictly necessary because central venous catheters carry a high risk of paradoxical air/thrombus embolism and catheter-related sepsis/brain abscess.

BGeneral Supportive Management and Precautions

  • Pregnancy is Strictly Contraindicated (mWHO Class IV — Class III): Maternal mortality in Eisenmenger syndrome is 30 to 50 percent (most deaths occur during delivery or the first postpartum week due to acute falls in SVR or thromboembolism), and fetal loss exceeds 40 percent. Reliable contraception (progestogen-only implants/pills or levonorgestrel IUD; avoid estrogen-containing contraceptives due to thrombosis risk) is mandatory; notice that Bosentan reduces progesterone efficacy via CYP3A4 induction, requiring barrier backup.
  • Avoidance of SVR Reduction and Dehydration: Strictly avoid dehydration, systemic arterial vasodilators (CCBs, ACEi/ARBs, alpha-blockers, nitrates), hot baths/saunas, and spinal/epidural anesthesia, as any fall in SVR acutely worsens R-to-L shunting and precipitates fatal hemodynamic collapse.
  • Phlebotomy and Iron Management: Routine therapeutic phlebotomy is strictly contraindicated (Class III). Isovolumic phlebotomy (removing 250 to 500 mL of blood with simultaneous equal-volume isotonic saline replacement) is restricted only to patients with moderate-to-severe hyperviscosity symptoms, hematocrit greater than 65 percent, and confirmed absence of dehydration or iron deficiency. Iron deficiency must be actively screened (serum ferritin and transferrin saturation) and treated cautiously with oral iron.
  • Anticoagulation Caveat: Routine oral anticoagulation is not recommended in all Eisenmenger patients due to high hemoptysis risk; it is reserved for patients with atrial fibrillation/flutter, documented pulmonary artery thrombosis, or prior embolic events with low bleeding risk.
Clinical Domain Guideline Recommendation (ESC 2020 / ESC-ERS 2022) Key Evidence / Clinical Rationale
Defect Closure in ES Class III (Harm): Strictly contraindicated Shunt acts as an essential RV decompression “pop-off valve”; closure causes acute RV failure and death
First-Line PAH Therapy Class I (Level B): Bosentan in symptomatic WHO FC III ES BREATHE-5 Trial: Lowered PVRi and improved 6MWD without lowering systemic SpO2
Combination PAH Therapy Class IIa (Level C): PDE-5i (Sildenafil/Tadalafil) + ERA; non-IV prostanoids Avoids central-line paradoxical embolism and sepsis associated with IV epoprostenol
Routine Phlebotomy Class III (Harm): Contraindicated for asymptomatic high Hct Induces iron-deficient rigid microcytosis, increasing stroke risk; reserve only for symptomatic Hct >65%
Pregnancy (mWHO IV) Class III (Contraindicated): 30–50% maternal mortality Use progestogen-only contraception (add barrier if on Bosentan due to CYP3A4 interaction)

VSURGICAL AND INTERVENTIONAL CONSIDERATIONS

  • Strict Contraindication to Shunt Closure (Class III): Surgical or percutaneous closure of the defect is strictly contraindicated once Eisenmenger physiology is established. Although unoperated Eisenmenger patients have markedly better medium-term survival than idiopathic PAH (because the defect unloads the RV and preserves systemic cardiac output), closing the defect converts the patient into severe uncompensated PAH with rapid RV failure.
  • Transplantation: Heart-Lung Transplantation or Bilateral Lung Transplantation with concomitant intracardiac defect repair is the only definitive surgical option for patients failing maximal medical therapy (10-year post-transplant survival is approximately 50 percent).

VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • High Burden of Late-Presenting Shunts: Delayed childhood detection of large VSDs, PDAs, and ASDs in rural India makes Eisenmenger syndrome a major cause of adult congenital cyanotic heart disease.
  • “Treat-and-Repair” in Borderline (Non-Eisenmenger) PAH-CHD: While true Eisenmenger syndrome (net R-to-L shunt) must never be closed, borderline patients presenting with elevated PVR (5 Wood Units or greater) who still maintain a net left-to-right shunt (Qp:Qs greater than 1.5) without resting/exercise desaturation may undergo a 6-month trial of targeted PAH therapy (ERA + PDE-5i) followed by repeat RHC; if PVR drops below 5 WU, fenestrated closure may be considered (Class IIb).
  • Iron Deficiency Surveillance: Because nutritional and parasitic iron deficiency is widespread in India, a hemoglobin of 14 to 15 g/dL in an Eisenmenger patient with SpO2 of 75 percent represents severe iron-deficient relative anemia; regular monitoring of MCV, serum ferritin, and transferrin saturation with judicious iron repletion prevents hyperviscosity strokes.
  • Air Travel and Non-Cardiac Surgery: Commercial aircraft cabins are pressurized to an equivalent altitude of 1,800 to 2,400 meters; although most stable Eisenmenger patients tolerate flight if well hydrated, supplemental in-flight oxygen is advised for patients with resting SpO2 below 85 percent or NYHA Class III/IV symptoms, and all non-cardiac surgeries must be performed in tertiary ACHD centers with air-bubble filters on all intravenous lines.

Key references

  • Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
  • Galiè N, Beghetti M, Gatzoulis MA, et al. (BREATHE-5 Investigators): Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study, Circulation, 2006.
  • Humbert M, Kovacs G, Hoeper MM, et al.: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, European Heart Journal, 2022.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.